Ray Dalio
NTLA icon

Ray Dalio’s Intellia Therapeutics NTLA Stock Holding History

Ray Dalio’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-223,166
Closed -$2.01M – 1159
2025
Q4 		$2.01M Buy
+223,166
New +$3.07M 0.01% 767
2023
Q1 		– Sell
-9,387
Closed -$328K – 841
2022
Q4 		$328K Buy
+9,387
New +$446K ﹤0.01% 763
2022
Q2 		– Sell
-4,907
Closed -$357K – 1045
2022
Q1 		$357K Buy
+4,907
New +$416K ﹤0.01% 923

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ray Dalio's NTLA Position: Q1 2026 in Review

Ray Dalio sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 223,166 shares — an estimated $2.01M sold.

Ray Dalio first reported a position in NTLA in Q1 2022 and held it in 3 quarters. The position peaked at $2.01M in Q4 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Ray Dalio reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ray Dalio sold 223,166 Intellia Therapeutics shares in Q1 2026, an estimated $2.01M.
  • Ray Dalio first reported a position in Intellia Therapeutics in Q1 2022 and held it in 3 quarters.
  • Ray Dalio's Intellia Therapeutics position peaked at $2.01M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.